United Therapeutics (NASDAQ:UTHR) Raised to Strong Sell at The Goldman Sachs Group

United Therapeutics (NASDAQ:UTHR) was upgraded by research analysts at The Goldman Sachs Group to a “strong sell” rating in a research report issued on Thursday, Zacks reports.

Other analysts also recently issued reports about the company. Royal Bank Of Canada cut their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Weiss Ratings cut shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Bank of America lowered their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. boosted their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $621.00.

United Therapeutics Stock Down 3.5%

Shares of NASDAQ:UTHR opened at $472.21 on Thursday. United Therapeutics has a 52-week low of $409.07 and a 52-week high of $609.35. The stock has a market cap of $20.25 billion, a P/E ratio of 16.89, a PEG ratio of 2.49 and a beta of 0.56. The business has a fifty day moving average of $512.06 and a two-hundred day moving average of $540.50.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the previous year, the firm earned $6.41 EPS. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, equities analysts anticipate that United Therapeutics will post 26.21 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Paul Mahon sold 8,300 shares of the stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $497.54, for a total transaction of $4,129,582.00. Following the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $22,474,876.88. This represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Nilda Mesa sold 228 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $505.87, for a total transaction of $115,338.36. Following the completion of the transaction, the director directly owned 5,580 shares of the company’s stock, valued at approximately $2,822,754.60. The trade was a 3.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 355,553 shares of company stock worth $184,183,266 over the last three months. Company insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. BlackRock Inc. purchased a new position in United Therapeutics in the second quarter valued at $2,868,735,000. Janus Henderson Group PLC boosted its stake in shares of United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after buying an additional 70,829 shares during the period. Jupiter Topco LLC acquired a new position in shares of United Therapeutics during the second quarter worth about $450,140,000. Norges Bank purchased a new stake in shares of United Therapeutics during the fourth quarter worth approximately $293,418,000. Finally, Swedbank AB lifted its stake in United Therapeutics by 0.7% in the first quarter. Swedbank AB now owns 327,122 shares of the biotechnology company’s stock worth $193,977,000 after acquiring an additional 2,350 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics is deploying the remainder of its $2 billion share-repurchase authorization through an accelerated share repurchase. A lower share count could support earnings per share and provide some demand for the stock, although investors may continue to debate the capital-allocation decision. United Therapeutics: Strong Catalyst Flow Bodes Well For Near-Term Growth
• Neutral Sentiment: The company’s latest quarterly results exceeded EPS expectations, with $7.27 in adjusted earnings versus an estimated $6.86. However, revenue of $783.3 million missed estimates and declined 1.9% year over year, reinforcing investor focus on whether newer therapies can offset pressure on the established business.
• Negative Sentiment: Goldman Sachs initiated coverage of UTHR with a Sell rating and a $321 price target. The analyst argued that the stock’s premium valuation is inconsistent with a shrinking core business and a challenging launch outlook for Tyvaso and Jenraldi. United Therapeutics downgraded to Sell
• Negative Sentiment: The Goldman report cited reimbursement and payer risks, generic competition, and uncertainty over real-world adoption of Jenraldi. Investors are also watching whether nebulized Tyvaso can secure broader coverage, which could affect future revenue growth. United Therapeutics slips as new Sell rating pressures shares
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $4.7 million, reducing her holdings by 2.84%. The transaction may weigh on sentiment, particularly alongside reported insider selling without recent purchases, though it may also reflect routine personal financial planning. SEC insider transaction filing

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.